Multiple myeloma and amyloidosis begin the same way – in plasma cells, white blood cells that help your immune system. But multiple myeloma (MM) is a rare blood cancer while amyloidosis is a ...

Amyloidosis is a condition associated with multiple myeloma. In amyloidosis, the abnormal plasma cells create many light-chain proteins that can form amyloid deposits.

Multiple myeloma and AL amyloidosis link to plasma cells in the bone marrow. The conditions co-occur in 10–15% of people with MM. Read about the connection.

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

People often have both amyloidosis and multiple myeloma. Anemia: It's one of the symptoms of multiple myeloma. It happens when too few red blood cells are in your body.

"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today ...

Darzalex is a monoclonal antibody used to treat adults with multiple myeloma and light chain amyloidosis. Good Response to Treatment. Daratumumab attaches to the CD38 protein, ...

AL amyloidosis is diagnosed in as many as 10 to 15% of patients with myeloma, and 38% of patients with myeloma have Congo red–positive deposits in subcutaneous fat aspirates, bone marrow ...

Ríos-Tamayo R, Krsnik I, Gómez-Bueno M, et al. AL amyloidosis and multiple myeloma: A complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel) . 2023;13(7):1518.

Multiple myeloma is a cancer of the plasma cells in the bone marrow, but it can impact everything from bone density to kidney function. ... and no signs of a condition called amyloidosis ...

Researchers at the Cima University of Navarra (Spain), in collaboration with the Spanish Myeloma Group (GEM-PETHEMA), have developed a calculator that identifies patients with multiple myeloma and ...

"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today.